Wren Laboratories announced Thursday that it finalized a distribution agreement with Kindstar Globalgene Technology to distribute Wren's blood-based neuroendocrine tumor NETest throughout China.

ChromaCode on Thursday announced a partnership with cancer diagnostic laboratory Protean BioDiagnostics to launch a test for non-small cell lung cancer through an early access program.

Amoy Diagnostics Co., Ltd (AmoyDx), a China-based innovative molecular diagnostics company, announced that it has entered into a Companion Diagnostic Collaboration Agreement with AstraZeneca, a global biopharmaceutical company.

Next-generation sequencing data analysis platform company One Codex said on Thursday that it has formed a partnership with Swiss clinical product manufacturer 4bases to bring sample-to-report microbiome analysis solutions to clinicians in the EU.

Molecular diagnosis refers to the technique of using molecular biological methods to detect changes in the structure or expression level of genetic material in patients to make a diagnosis.

To address challenges with error-prone, manual molecular testing workflows, Thermo Fisher Scientific today has introduced Diomni Enterprise Software, helping streamline routine diagnostics testing for standardization and faster time-to-results. By connecting workflow steps within one interface, Diomni Enterprise can increase a lab’s ability to dynamically respond to today’s rapidly changing testing environment. The solution can be used by a variety of labs performing routine quantitative polymerase chain reaction (qPCR) diagnostic tests and by developers to increase the speed of innovation for emerging testing solutions.

Fortis Life Sciences on Wednesday said it has acquired diagnostic testing component maker International Point of Care.

Alveo Technologies said on Tuesday that it has partnered with Germany's Fraunhofer Institute for Cell Therapy and Immunology IZI to develop molecular diagnostic tests for the veterinary space.

Helio Genomics said Thursday that its sister company, Laboratory for Advanced Medicine & Health Group (LAMH), has received approval from the National Medical Products Administration (NMPA) in China for its cell-free DNA-based liver cancer detection test. The assay is the first of its kind to receive this approval.

The US Food and Drug Administration announced on Tuesday that it has launched a voluntary pilot program intended to reduce the risks of laboratory-developed tests used to select patients for oncology therapies.